Derms on Drugs (Scholars in Medicine)
Explore every episode of Derms on Drugs
| Pub. Date | Title | Duration | |
|---|---|---|---|
| 31 Jan 2025 | Melanoma Meltdowns, Biosimilar Betrayals, and the Eczema Enigma Exposed! | 01:01:03 | |
Buckle-up Kids. Our Derms on Drugs are answering some of the hottest questions in dermatology again this week:
But wait, there's more! We'll also dive into:
You’ll laugh, you’ll cry, you might even learn something new… Join Drs. Ferris, Zirwas and Patton for a new episode every Friday Derms on Drugs is produced by Scholars in Medicine. Guest: Ian A. Myles, MD, Mph Guest Bio: Dr. Myles, Principal Investigator, Epithelial Therapeutics Unit, graduated with a B.S. in biology from Colorado State University in 2001 and then obtained an M.D. from the University of Colorado in 2005. He completed an internal medicine residency at The Ohio State University prior to beginning fellowship training in allergy and clinical immunology at NIH. He worked under the mentorship of Dr. Sandip Datta investigating the mechanistic details of susceptibility to S. aureus skin infections. In 2011, Dr. Myles became a commissioned officer in the United States Public Health Service Commissioned Corps. LCDR Myles has supported several USPHS missions, from the Ebola virus vaccine trial in West Africa to congressional Gold Medal Ceremonies at the U.S. Capitol. In 2013, he was awarded a position as an assistant clinical investigator in the NIAID Transition Program in Clinical Research. Dr. Myles received his M.P.H. from George Washington University in 2016. In 2018, Dr. Myles became the head of the newly formed Epithelial Therapeutics Unit to evaluate the efficacy and safety of a topical, live bacterial treatment for atopic dermatitis (eczema). He is currently a participant in the Lasker Clinical Research Scholars and Distinguished Scholars programs. Links to Articles and Websites 3. The clinical, mechanistic, and social impacts of air pollution on atopic dermatitis 5. Environmental and behavioral mitigation strategies for patients with atopic dermatitis 6. Acne Relapse and Isotretinoin Retrial in Patients With Acne 9. Ferulic Acid in the Treatment of Papulopustular Rosacea: A Randomized Controlled Study 11. Effectiveness of surgical versus non-surgical interventions in treatment of digital mucous cysts Melanoma Prognosis Calculator http://www.lifemath.net/cancer/melanoma/outcome/index.php
Skinesa Defensin+ Probiotic Spray | |||
| 21 Mar 2025 | Dermatology Fact or Fiction - The Derms on Drugs Find Some Serious Fiction in the Latest Articles in the Literature | 00:40:42 | |
New Articles on causes and treatments for AKs, Melasma, Atopic Derm, Acne, Grover's and Contact Derm. But you can't always believe what you read in a journal, and even when you can it doesn't mean it's going to help your patients. So, sit back, relax and join the Derms on Drugs to separate fact from fiction.
Derms on Drugs is brought to you by Scholars in Medicine. Resource links for this episode available at Scholars in Medicine.
| |||
| 28 Feb 2025 | The Derms on Drugs Take on Big Questions | 00:34:03 | |
-Big BCCs – Debulk First or Chemo First?; -Do Covid or the Covid Vaccine Affect the Risk of Getting a Bullous Disease? -Does Drinking Drive Melasma? But of course that’s not all: Should we be treating Strep to help our psoriasis patients get better faster? What Biologics are new on the horizon for treating linear morphea? And just how well does oral roflumilast work for psoriasis? Join us this week for more dermatology takes that you won’t get anywhere else! Derms on Drugs is brought to you by Scholars in Medicine. Resource links for this episode are available at Scholars in Medicine.
| |||
| 14 Mar 2025 | To Scratch or Not to Scratch, That Is the Question | 00:36:06 | |
The Derms on Drugs enlist the Sultan of Scratching, Dan Kaplan from the University of Pittsburgh, to answer the age- old question - should you scratch an itch or not? Believe it or not, some of the most cutting-edge science on the planet is focusing on this question (you think they'd have better stuff to work on, but who are we to judge). The answer(s) are going to surprise you - turns out scratching does a lot more than just get bugs off our skin (although that part is important too). Derms on Drugs is brought to you by Scholars in Medicine. Guest: Daniel H. Kaplan, MD, PhD Daniel H. Kaplan, MD, PhD is a Professor within the Department of Dermatology and Immunology, University of Pittsburgh. His research is dedicated to understanding the mechanisms that underlie skin immunity and the interplay of different immune cells types that reside in the skin. As a graduate student at Washington University, St Louis he participated in the re-invigoration of the concept of tumor immunosurveillance by observing an increased frequency of skin tumors in immunodeficient mice. During his post-doc at Yale University, he developed a number of mouse lines with a selective deficiency of Langerhans cells (LC) and showed that these cells have the unexpected capacity to suppress tissue immune. As an Assistant and later Associate professor at the University of Minnesota, he found that LC and dermal dendritic cells have unique functions in the development of anti-pathogen responses. In 2015 he moved to the University of Pittsburgh. His laboratory is currently focused on understanding how intracellular communication mechanisms between immune cells and non-hematopoietic cells in the skin with a particular emphasis on sensory afferents modulate cutaneous immunity and skin disease. Resource links for this episode are available at Scholars in Medicine.
| |||
| 14 Feb 2025 | Derms on Drugs Debunks the "Benzene in Benzoyl Peroxide" Story | 00:34:55 | |
We all kind of freaked out when the news broke that benzene had been detected in benzoyl peroxide. I mean, makes sense, right -benzene even sounds like benzoyl - how did nobody think of this before! And the lab that detected it got Zantac pulled from the market and it was even discussed at Fall Clinical..."There is no safe amount of exposure to benzene..." The final straw was when an article dropped in JID -JID for goodness sake - about the problem. Not so fast. Our trio did a deep dive and there is WAY more to this story than meets the eye. Join us as we get into the nitty grittywith John Barbieri (from Harvard!) about his published research on the topic along with the well known Australian cosmetic chemist, Michelle Wong, PhD (aka "Lab Muffin"). Derms on Drugs is produced by Scholars in Medicine. John Barieri John Barbieri, MD, MBA is an Assistant Professor at Harvard Medical School and the Director of the Advanced Acne Therapeutics Clinic at the Brigham and Women’s Hospital. He is an associate editor at JAMA Dermatology and is also the co-chair of the American Academy of Dermatology Acne Guidelines Work Group. His research is focused on conducting innovative clinical trials, health economic, and epidemiology studies to identify the best approaches to care for patients with acne. He also focuses on exploring the role of patient-reported outcomes to ensure we are capturing the patient’s voice and perspective on their care. Dr. Barbieri has received consulting fees from Honeydew Care. Michelle Wong Michelle Wong is a science educator and chemistry PhD. In 2011 she started the website Lab Muffin Beauty Science, where she explains the science behind beauty products for a general audience. She has since expanded to YouTube, Instagram and TikTok, and is known for her work debunking myths. Her book The Science of Beauty was released in June 2024, and she is the cofounder of BeautySciComm. Through her science communication work, Michelle has worked with many brands on campaigns, and delivered invited talks at international conferences. Her work has been featured in Wired, The New York Times, ABC News, and Chemistry & Engineering News. Social media handles: YouTube, IG, Threads, TikTok: @labmuffinbeautyscience Bluesky: labmuffin.com Website: labmuffin.com Substack: labmuffin.substack.com Resources: 1. Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products PubMed: https://pubmed.ncbi.nlm.nih.gov/39384016/ Full Text Link: www.jidonline.org/action/showPdf?
PubMed: https://pubmed.ncbi.nlm.nih.gov/38950699/ Full Text: https://www.jaad.org/article/S0190-9622(24)00980-0/fulltext
3. Benzoyl peroxide for acne treatment is not associated with an increased risk of malignancy: A retrospective cohort study PubMed: https://pubmed.ncbi.nlm.nih.gov/39002561/ Full Text: https://www.jaad.org/article/S0190-9622(24)01051-X/fulltext
4: Benzene in your products, Part 2: The story of Valisure. Lab Muffin Beauty Science. https://labmuffin.com/benzene-in-your-products-part-2-the-story-of-valisure/ 5: Shelf-stable formulations of benzoyl peroxide and methods of producing same https://patents.google.com/patent/WO2023177625A1/en 6. A Legal Shakedown Exposed: How Valisure tried to cash in on its dubious claims about cancer. https://www.wsj.com/articles/valisure-cancer-claims-zantac-dry-shampoo-david-Iight-11675806424 | |||
| 31 Jan 2025 | Rinvoq v Dupi: Battle of the Century, Deadly Boxed Warnings, and Ending the Long Term Relationship with AKs | 01:08:28 | |
Buckle up! We're diving deep into the wild world of dermatology, where the only thing more dangerous than a weird mole is a boxed warning. Here's what's cooking in this episode:
Plus, we'll tackle burning questions like: Are JAK inhibitors the new Russian roulette? Is switching IL-23s just dermatological musical chairs? And is Topical Steroid Withdrawal the new gluten intolerance?Join us as we dive into the best articles of the last week. Warning: Side effects may include uncontrollable laughter, raised eyebrows, and a sudden urge to moisturize. Join Drs. Ferris, Zirwas and Patton for a new episode every Friday. Derms on Drugs is produced by Scholars in Medicine. | |||
| 21 Feb 2025 | Psoriasiform Dermatitis and Idiopathic Erythroderma - The Derms on Drugs Clear Up Some Murky Topics | 00:43:14 | |
Psoriasiform Dermatitis - the Derms on Drugs take on your worst nightmare when it comes to path reports. Dermatitis? Psoriasis? Both? Neither? We'll get into the weeds with Amber Atwater, who looked at what the final diagnoses ended up being in hundreds of patients with psoriasiform dermatitis that gives us some clues on how to approach these patients. We also review the latest work on idiopathic erythroderma - not so idiopathic anymore, thanks to the hard work and genius of Shawn Kwatra at the University of Maryland. And, stick around to the end for some hard hitting trivia on the American Contact Dermatitis Society's last 25 years of Allergens of the Year. Join us for another episode of Derms on Drugs, brought to you by Scholars in Medicine. 1. Targeted dual biologic therapy for erythroderma of unknown etiology guided by high-parameter peripheral blood immunophenotyping 2. Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors 3. Final clinical diagnosis in cases of histopathologic psoriasiform dermatitis: retrospective cross-sectional analysis of a Southeastern United States population, 2004-2017 4. Epidermal spongiotic Langerhans cell collections, but not eosinophils, are a clue to the diagnosis of allergic contact dermatitis: A series of 170 clinically- and patch test-confirmed cases 5. The 2023 Annual Report of DataDerm: The database of the American Academy of Dermatology 6. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis 7. The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement 8. Toluene-2,5-Diamine Sulfate: Allergen of the Year 2025 | |||
| 07 Feb 2025 | BCC Treatment Goes Viral: Find out what happens when you unleash a genetically modified herpes virus on difficult BCCs | 01:02:12 | |
Derms on Drugs is produced by Scholars in Medicine.
Jacob P. Thyssen, MD, PhD, DmSci Dr. Thyssen has spent nearly 20 years as a clinical dermatologist at university hospitals in Copenhagen, where he currently serves as a professor emeritus. His research in inflammatory skin diseases and allergy has earned him numerous awards. Dr. Thyssen has co-authored more than 700 peer-reviewed articles, with his work appearing in prestigious journals such as The Lancet and NEJM. He holds PhD and medical doctor degrees and has been a research fellow at Harvard Medical School, Boston, UCSF in San Francisco, and a visiting professor at UZH in Zürich. Resources: 1. Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial) | |||
| 28 Mar 2025 | Best of AAD 2025: The Hottest of the Hot Dermatology Data | 00:33:21 | |
Late-breaking abstracts from the AAD Meeting offer a sneak peek into dermatology’s future—and we’ve done the heavy lifting for you. Derms on Drugs uncovers the hottest data that will dominate the top journals and meetings in 2025: the cutting-edge for psoriasis, new Tyk2 inhibitors, new treatment for cutaneous lupus, dupilumab’s possible role in bullous pemphigoid, patient-led patch testing innovations, plus fresh approaches to skin cancer and alopecia areata. Tune in to stay ahead of the curve! This podcast is brought to you by Scholars in Medicine. | |||
| 31 Jan 2025 | Litfulo Lowdown: When to Wave Goodbye; Olumiant Showdown: Solo vs. Squad; Solar Shocker: More Sun Equals Less Death? | 00:58:52 | |
Is your Litfulo not pulling its weight? New research gives you the inside scoop on when to throw in the towel We’re buzzing about oral JAK inhibitors for vitiligo, but do they really outshine NBUVB alone? We’ve got the answer And guess what? While basking in the sun might up your skin cancer risk, it turns out those rays also help you dodge death from heart disease, cancer and other nasty surprises— at least if you happen to be living in England Join Richard Weller, the genius behind these sacrilege statements, as he helps us rethink how we guide our patients on sun exposure—taking into account their skin type and the sunny vibes of their locale. We’ll also dive into Dupixent’s surprising benefits for cancer immunotherapy, its heart-friendly profile, and how it shields kids from ADD, depression, and anxiety. Ever wonder if switching up your psoriasis biologic is worth it? We’ll tackle that enigma. And don’t miss our head-to-head trial of Pregabalin vs. Gabapentin for the intensely itchy, plus a look at the long-term risk of psoriasis after a first bout of guttate psoriasis. Oh, and do we really need sterile gloves in derm surgery? Tune in for all this and more—with the trusty team at Derms on Drugs! Join Drs. Ferris, Zirwas and Patton for a new episode every Friday Derms on Drugs is produced by Scholars in Medicine. Guest: Richard Weller, Professor I graduated in medicine at St Thomas’ Hospital, University of London (now part of King’s College, London) and undertook my general/internal medicine training in the north of England and in Australia.Having gained my MRCP I trained in dermatology at the Institute of Dermatology (St John’s) in London, and in Aberdeen and Edinburgh. I spent some time out of my clinical training to complete a research MD degree. Having completed my dermatology training, I gained a scholarship from the University of Edinburgh, and spent three years in post-doctoral research training in the laboratories of Prof Victoria Kolb-Bachofen, Heinrich-Heine Universität, Dusseldorf, and of Dr Tim Billiar, University of Pittsburgh, USA.I was recruited from America to the post of Senior Lecturer, and latterly Reader in Dermatology and Associate Principal Investigator at the Centre for Inflammation Research, University of Edinburgh.My time is divided between clinical duties, where I am an honorary NHS Consultant Dermatologist with a particular interest in medical dermatology and eczema, and the University where I have an active research group, and also a significant teaching commitment as Programme Director of the M.Med.Sci degree.
| |||
| 07 Mar 2025 | Compliance, Adherence - Whatever, Just Put the D*mn Cream On... | 00:46:12 | |
The Captain of Compliance, The Admiral of Adherence... Whatever you want to call him, you're going to love this week's episode as the Derms on Drugs dig deep with Dr. Steve Feldman on how to help our patients actually follow through with our recommendations. Trust us, even if you've heard Dr. Feldman talk about this before, you're still not going to want to miss this. As part of our dive into the nitty gritty of adherence we'll also talk about: Derms on Drugs is brought to you by Scholars in Medicine. Guest: Dr. Steven R. Feldman, MD, PhD is a Professor of Dermatology, Pathology, and Social Sciences & Health Policy at the Wake Forest School of Medicine. His chief clinical interest is psoriasis. Feldman has done groundbreaking research on addiction to tanning beds, patients’ adherence to their medication treatment regimens, and patients’ satisfaction with their medical care. Feldman’s experiences in medicine have led him to try to see how others perceive things, leading to his book Compartments and his recent novella Bent Toward Justice. His research has been published in over 1,000 peer reviewed, Medline-referenced articles. Expertscape.com ranks Feldman among the top experts in the world on psoriasis, acne, dermatology, and treatment adherence. Feldman also serves as the editor of the Journal of Dermatological Treatment and the Journal of Dermatology and Dermatological Surgery and as chief medical editor of The Dermatologist. Resource links for this episode available at Scholars in Medicine: 1. FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis | |||